The American Urological Association (AUA) has officially amended its clinical guideline on Renal Masses and Localized Renal Cancer.1
"Renal cancer is one of the ten most common cancers in both men and women," Steven C. Campbell, MD, PhD, chair of the AUA Renal Mass Guideline Panel, stated in a press release. "We believe this revised guideline will provide a useful, evidence-based clinical reference for the medical and surgical management of renal masses and localized renal cancer."
The guideline was initially published in 2013 and was last amended in 2017. The following sections summarize the updates made to the guideline.
Patients aged ≤46 years with renal malignancy and patients with multifocal or bilateral renal masses should definitively be recommended for genetic counseling. Three other situations in which the guidelines stipulate that clinicians should recommend genetic counseling are:
When tumor size, RMB, and/or imaging indicated increased oncologic potential, radial nephrectomy should be considered for patients with a solid or Bosniak 3/4 complex cystic renal mass.
The final update the AUA made is that there is now an “other considerations” section in the guideline.
For additional information on the update, the full guideline can be accessed online.
Reference
1. American Urological Association Announces Updates to Clinical Guidance for Renal Mass and Localized Renal Cancer. Published online May 26, 2021. Accessed June 1, 2021. https://prn.to/34BsnfJ.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.